Because the World Well being Group just lately issued steering supporting the usage of GLP-1 drugs in weight problems care, these medication reached a brand new milestone. For sufferers, it marks a much-needed shift away from willpower-based narratives and towards understanding weight as one thing rooted in biology.
However lengthy earlier than Ozempic and Wegovy turned family names, the story of GLP-1s began with early gut-hormone analysis—and an unlikely breakthrough courtesy of a venomous desert lizard. Beneath, consultants stroll us via the science of GLP-1s: the place it started, what we’ve realized and the place the sphere is headed subsequent.
Featured Consultants
- Amanda Kahn, MD is a board-certified internist and longevity skilled in New York
- Andrea Traina, Pharm D, is an weight problems director at Novo Nordisk
- Eduardo Grunvald, MD is a board-certified internist and weight problems medication specialist in San Diego, CA
The Intestine Hormone That Virtually Didn’t Make It
Within the Nineteen Eighties and Nineties, researchers have been attempting to know how the physique regulates blood sugar after meals. That work led to the invention of glucagon-like peptide-1 (GLP-1), a hormone launched from the small gut that helps management insulin secretion, gradual digestion and scale back urge for food. “Early researchers seen that GLP-1 powerfully and appropriately stimulated insulin solely when glucose ranges have been excessive, that means it lowered blood sugar with out inflicting harmful hypoglycemia,” says New York internist and longevity skilled Amanda Kahn, MD. “It additionally slowed gastric emptying and lowered urge for food, which instantly made it totally different from different diabetes hormones.”
The issue was timing: pure GLP-1 is damaged down inside minutes, making it impractical as a medicine. For some time, it appeared like promising biology with no path ahead.
Enter the Gila Monster
Then the reply arrived from an sudden place: the Gila monster, a venomous desert lizard identified for consuming sometimes and surviving lengthy intervals with out meals. “The saliva of the Gila monster creates a substance that appears similar to the GLP-1 our physique naturally makes,” explains Andrea Traina, PharmD, weight problems medical director for Novo Nordisk. “What the Gila monster makes is Exendin 4. This turned the idea for exenatide, the primary GLP-1 receptor agonist medicine accredited in 2005. It was short-acting, lasted a couple of hours and was dosed twice a day earlier than meals. That little lizard utterly revolutionized our understanding of urge for food management, and glucose metabolism,” says Traina. “The scientific neighborhood has realized a lot from it.”
What made Exendin 4 totally different was sturdiness. It resisted speedy breakdown, giving scientists a blueprint for designing longer-acting medication. “That little lizard utterly revolutionized our understanding of urge for food management, glucose metabolism and irritation,” says Traina. “We’ve got realized a lot from it.”
From Diabetes Drug to Weight-Loss Device
When exenatide reached diabetes clinics, docs seen one thing sudden. Sufferers not solely improved their blood sugar ranges but additionally misplaced significant weight. “Clinicians started noticing vital weight reduction in diabetes sufferers taking early GLP-1 medication like exenatide and liraglutide within the mid-2000s,” says Dr. Kahn. “The turning level got here round 2015, when higher-dose liraglutide, underneath the model identify Saxenda, was accredited for weight problems, confirming the load loss impact wasn’t only a facet impact, however a major therapeutic motion.”
GLP-1s labored otherwise from earlier weight loss program medication. “The rationale many individuals battle to drop some weight with life-style modifications alone is that the biology will get in the way in which,” says San Diego internist and weight problems specialist Eduardo Grunvald, MD. “These drugs scale back starvation, cravings and the reward response to high-fat, high-sugar meals, serving to individuals really feel full with much less meals.” For a lot of sufferers, that shift reveals up as quiet. Fewer cravings. Much less meals noise.
Semaglutide, the energetic ingredient in Wegovy and Ozempic, pushed the category additional. Giant trials confirmed advantages that prolonged past weight alone. “We’ve got a medicine that’s well-known, revered and confirmed secure and efficient past the dimensions,” notes Traina. “Not simply weight discount, however reductions in coronary heart assault, stroke and cardiovascular loss of life.” These findings helped reposition GLP-1s as long-term metabolic therapies somewhat than short-term fixes.
The place the Science Is Headed Now
The following section of the GLP-1 story is much less about format and extra about stability within the physique over time, a shift that turned tangible in December 2025 when the FDA accredited Novo Nordisk’s oral semaglutide (Wegovy), the primary every day GLP-1 tablet cleared for weight problems remedy. What was as soon as investigational is now actuality. As scientists realized how one can make these drugs last more in our programs, the main target shifted as to whether that very same consistency may lengthen past injections. “We now have a medicine that’s confirmed for security and efficacy past the dimensions obtainable in a every day tablet with an analogous security and efficacy profile to the once-weekly injection,” says Traina. “That’s actually first of its form.”
Getting there took many years. “GLP-1s are peptide-based molecules that aren’t designed to be absorbed orally,” Traina explains. “It took years of analysis to develop a formulation that quickly modifications the abdomen surroundings, protects the drug from being damaged down and permits sufficient semaglutide to be absorbed to have a therapeutic impact.”
The Tablet Period Begins
In late-stage trials, sufferers taking the very best oral dose of Wegovy misplaced about 14 p.c of their physique weight, outcomes similar to the injectable model. Like its once-weekly counterpart, the tablet can be accredited to scale back cardiovascular threat, reinforcing the concept that GLP-1 drugs are actually seen as long-term metabolic therapies somewhat than short-term weight-loss instruments.
The pill should be taken on an empty abdomen, with a 30-minute window earlier than consuming, reflecting the precision required to permit absorption within the digestive tract. Nonetheless, the approval marks a significant enlargement in entry. Weekly injections stay foundational, however every day oral remedy provides one other entry level into care, significantly for sufferers hesitant about needles or looking for a remedy that matches extra seamlessly right into a morning routine.
What the Lizard Began
Whereas the story begins with a lizard, its influence reaches a lot additional. “GLP-1 confirmed us that the intestine has been performing like an endocrine organ all alongside,” says Dr. Kahn. “By taking note of it, we uncovered some of the highly effective instruments for metabolic well being and longevity that medication has recognized.”
For many individuals on GLP-1s, the expertise has been quietly validating—confirming that what they have been lacking wasn’t willpower however the organic swap that silences meals noise, a discovery that traces all the way in which again to the Gila monster.
